Terazosin Hydrochloride Capsule
Product Images NDC 69292-204

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 69292-204). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amici Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

201-01 (69292 201 01)

Terazosin Capsules USP 1 mg oral capsules from Amici Pharma, Inc. The label includes NDC 69292-201-01, a barcode, and medication instructions stating that the medication guide is provided separately. The package contains 100 capsules and is marked for prescription use only.*

FDA Label Image

201-10 (69292 201 10)

Terazosin Capsules, USP 1 mg oral capsules label by Amici Pharma, Inc. The label includes dosage strength of 1 mg, NDC number 69292-201-10, and indicates a package size of 1000 capsules. Storage instructions and a barcode are also visible, along with caution to keep the medication out of reach of children.*

FDA Label Image

202-01 (69292 202 01)

Label for Terazosin Capsules USP 2 mg by Amici Pharma, Inc. The oral capsule packaging contains 100 capsules, with instructions for pharmacists to dispense medication guides and keep the capsules in original containers. The label includes NDC 69292-202-01, directions for storage, a barcode, and the Amici Pharma logo.*

FDA Label Image

202-10 (69292 202 10)

Label of Terazosin Hydrochloride Capsules USP 2 mg by Amici Pharma, Inc. The label includes the dosage strength (2 mg), NDC number 69292-202-10, and states a package size of 1000 capsules. It includes pharmacist instructions to dispense the medication guide separately, storage conditions, and barcode information. The capsules are for oral use only.*

FDA Label Image

203-01 (69292 203 01)

Label for Terazosin Capsules USP 5 mg by Amici Pharma, Inc. The label indicates prescription use with 100 capsules in the package. The label includes detailed drug content and handling instructions, the NDC 69292-203-01, and a barcode. It also notes the vial size as Non Varnish A PM, 70 L x 24 H x 46 mm W.*

FDA Label Image

203-10 (69292 203 10)

Terazosin Capsules, USP 5 mg oral capsules packaging label from Amici Pharma, Inc. The label includes dosage strength, instructions for pharmacists to dispense medication guides separately, container safety warnings, storage instructions, and the product NDC barcode. The package size is 100 capsules.*

FDA Label Image

204-01 (69292 204 01)

Label for Terazosin Hydrochloride Capsules, USP 10 mg, oral capsule form, packaged in a bottle of 100 capsules. The label includes directions to dispense a medication guide with each prescription. The product is labeled by Amici Pharma, Inc., with NDC 69292-204-01 shown. The label displays storage instructions, barcode, and regulatory information.*

FDA Label Image

204-10 (69292 204 10)

Label for Terazosin Hydrochloride Capsules, USP 10 mg by Amici Pharma, Inc. The label shows the proprietary name Terazosin with a strength of 10 mg. It is an oral capsule dosage form in a package of 1000 capsules. The label includes NDC 69292-204-10 and dispensing instructions for pharmacists.*

FDA Label Image

Terazosinhydrochloridechemicalstructure (Chemicalstructure)

Chemical structure diagram of Terazosin Hydrochloride depicting its molecular arrangement, including aromatic rings, ether groups, a piperazine ring, and a lactam moiety, along with the hydrochloride salt component.*

FDA Label Image

Figure1 (Figure1)

Two line graphs showing changes in clinical parameters over three months comparing Terazosin Hydrochloride and placebo. The left graph displays mean change in total symptom score from baseline, where Terazosin shows greater symptom reduction. The right graph shows mean increase in peak flow rate in mL/sec from baseline, with Terazosin demonstrating higher improvement than placebo. Sample sizes range from 52 to 55 per group.*

FDA Label Image

Figure2 (Figure2)

A line graph depicting mean change from baseline over 30 months. The x-axis shows months (0, 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30) and the y-axis shows mean change values ranging from 0 to -7. Data points are plotted with markers, and several have asterisks indicating statistical significance.*

FDA Label Image

Figure3 (Figure3)

A line graph showing the mean change from baseline in mL/sec over a 30-month period with error bars. Data points are marked at intervals ranging from month 0 to month 30, with several points indicated by asterisks, suggesting statistical significance. The y-axis measures mean change from baseline in mL/sec, and the x-axis represents time in months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.